MET and non-small cell lung carcinoma: A disease control rate of 80% was achieved in 65 subjects, and more responses were observed in patients with MET amplification.53 Similar results were reported in the combination therapy of capmatinib with other EGFR inhibitors, such as erlotinib.54 Due to its significant efficacy compared to existing therapies, capmatinib granted a breakthrough therapy designation by the FDA for NSCLC patients harboring MET exon 14 skipping mutations in 2019 and was approved for this indication on May 6, 2020.